Complete Response to Pembrolizumab in Advanced Colon Cancer Harboring Somatic POLE F367S Mutation with Microsatellite Stability Status: A Case Study
Authors Chen J, Lou H
Received 7 January 2021
Accepted for publication 24 February 2021
Published 9 March 2021 Volume 2021:14 Pages 1791—1796
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Gaetano Romano
Jianxin Chen,1 Haizhou Lou2
1Department of Medical Oncology, Quzhou People’s Hospital, Quzhou, 324000, Zhejiang, People’s Republic of China; 2Department of Oncology, Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, 310016, Zhejiang, People’s Republic of China
Correspondence: Haizhou Lou
Department of Oncology, Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Zhejiang, 310016, People’s Republic of China
Email [email protected]
Background: Polymerase epsilon (POLE) mutations are considered as one of the most potential and promising biomarkers for immune checkpoint inhibitors (ICIs) in patients with colorectal cancer. However, the treatment of ICIs sometimes also resulted in unsatisfactory results in patients with POLE mutations, which revealed that not all mutations on POLE contribute to tumor regression in colorectal cancer.
Case Presentation: We herein reported a case in which the patient with advanced colon cancer harboring somatic POLE F367S mutation, along with microsatellite stability status, has achieved efficacy of complete response to the programmed cell death 1 (PD-1) receptor inhibitor pembrolizumab, as well as a progression-free survival more than 49 months, and still in extension.
Conclusion: Somatic POLE F367S mutation might be presented as a sensitive predictor to pembrolizumab in patients with colon cancer.
Keywords: POLE mutation, colon cancer, pembrolizumab, complete response
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]